Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 95,262
  • Shares Outstanding, K 32,624
  • Annual Sales, $ 140 K
  • Annual Income, $ -9,530 K
  • 60-Month Beta -0.83
  • Price/Sales 682.77
  • Price/Cash Flow N/A
  • Price/Book 2.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.41 +24.07%
on 07/14/20
4.30 -30.47%
on 07/20/20
+0.44 (+17.25%)
since 07/07/20
3-Month
2.06 +45.15%
on 05/08/20
4.30 -30.47%
on 07/20/20
+0.92 (+44.44%)
since 05/07/20
52-Week
0.38 +684.78%
on 11/26/19
7.11 -57.95%
on 03/09/20
+0.92 (+44.44%)
since 08/07/19

Most Recent Stories

More News
LD Micro Announces Preliminary List of Presenters for the LD 500

LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACER : 5.41 (+21.03%)
ACU : 22.49 (+2.23%)
AEY : 2.37 (+2.60%)
ADIL : 1.8600 (-3.12%)
ADXS : 0.5500 (-3.44%)
AEHR : 2.12 (-6.05%)
AIM : 2.99 (+2.40%)
AIRI : 1.2700 (-4.51%)
KERN : 6.55 (-1.65%)
ALIM : 6.31 (-8.28%)
ALLT : 11.55 (+0.70%)
AMS : 2.16 (+0.93%)
ANVS : 5.55 (-2.12%)
APEN : 1.5000 (-7.41%)
APM : 3.54 (-0.28%)
AQB : 2.51 (-17.97%)
ARTL : 1.2499 (-0.01%)
ARHH : 0.7000 (-7.89%)
ATOM : 11.84 (-5.28%)
ATOS : 3.83 (-0.78%)
ACU.VN : 0.115 (unch)
AUTO : 1.7500 (-1.69%)
AYRO : 4.17 (-2.80%)
AYTU : 1.3800 (-0.72%)
AZRX : 1.1700 (+7.34%)
BLDP : 14.74 (-1.11%)
BELFA : 12.88 (+2.98%)
BCDA : 2.67 (-1.84%)
BIOC : 1.0100 (-11.40%)
BMRA : 8.81 (-0.68%)
BSGM : 7.43 (-2.49%)
BLNK : 11.85 (-2.67%)
BKEP : 1.4300 (unch)
CLBS : 2.44 (+4.72%)
CLXT : 5.59 (+7.50%)
ASUR : 7.31 (-0.27%)
BLGO : 0.1750 (-1.41%)
49 Public Companies to Present at the SNN Network Virtual Conference on August 3-6, 2020

The SNN Network Virtual Conference will take place on August 3 - 6, 2020, where 49 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.

AIM : 2.99 (+2.40%)
AZT.VN : 0.395 (-5.95%)
DUOT : 4.90 (-0.81%)
SOLO : 3.07 (-2.54%)
EFOI : 6.60 (+8.91%)
ESK.VN : 0.540 (+10.20%)
EXROF : 0.6930 (+0.93%)
XRO.CN : 0.920 (-1.08%)
CALI.CN : 0.115 (+43.75%)
FNNZF : 0.0747 (+9.21%)
FBIO : 3.05 (+3.74%)
GIGA : 4.0000 (-4.31%)
HBP.TO : 0.55 (+1.85%)
IDEX : 1.6300 (-1.81%)
ISDR : 17.10 (-0.29%)
LXXGF : 0.7374 (-1.54%)
OSS.VN : 0.445 (+2.30%)
RDHL : 8.75 (+9.51%)
REKR : 4.16 (+2.97%)
SZLS.TO : 0.060 (+9.09%)
TBP.VN : 0.215 (+2.38%)
TNXP : 1.1600 (-3.33%)
URG : 0.5400 (-2.37%)
GROW : 3.52 (+0.57%)
VNRX : 3.35 (+3.72%)
WWR : 2.17 (-5.24%)
AIM ImmunoTech to Present at the SNN Network Virtual Investor Conference on Monday, August 3rd

OCALA, FL / ACCESSWIRE / July 27, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it will be presenting at the SNN Network Virtual Investor Conference on Monday, August 3, 2020 at 1:30...

AIM : 2.99 (+2.40%)
AIM ImmunoTech Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center Supporting Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients with Cancer

Agreement Important Precursor to Next Step, EnrollmentAIM is a Study Collaborator and Financial Supporter

AIM : 2.99 (+2.40%)
AIM ImmunoTech Added to Russell Microcap(R) Index

OCALA, FL / ACCESSWIRE / June 29, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it has been added to the Russell Microcap® Index, following the annual Russell indexes reconstitution,...

AIM : 2.99 (+2.40%)
Thinking about buying stock in Soligenix Inc, Ekso Bionics, SINTX Technologies, AIM ImmunoTech, or Nio Inc?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNGX, EKSO, SINT, AIM, and NIO.

AIM : 2.99 (+2.40%)
EKSO : 6.26 (-2.64%)
NIO : 13.42 (-3.03%)
SNGXD : 4.1500 (-5.68%)
AIM ImmunoTech Provides Update on Commercial Launch of Ampligen(R) in Argentina for the Treatment of Chronic Fatigue Syndrome

Receives clearance from Argentina's FDA to import first shipment of Ampligen® for commercial sale in Argentina

AIM : 2.99 (+2.40%)
Le Groupe KDA Annonce la Nomination de Nouveaux Administrateurs

(via TheNewswire)

KDA.VN : 0.125 (-3.85%)
AIM : 2.99 (+2.40%)
KDA Group Announces Apppointments of New Directors

(via TheNewswire)

KDA.VN : 0.125 (-3.85%)
AIM : 2.99 (+2.40%)
AIM ImmunoTech Files Provisional Patent Application for the Use of Ampligen(R) as a Potential Therapy for COVID-19 Induced Chronic Fatigue

Notes reports of potential surge in CFS-like cases worldwide as a result of COVID-19, the disease caused by the SARS-CoV-2 coronavirus

AIM : 2.99 (+2.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AIM with:

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

2nd Resistance Point 3.09
1st Resistance Point 3.00
Last Price 2.99
1st Support Level 2.85
2nd Support Level 2.79

See More

52-Week High 7.11
Fibonacci 61.8% 4.54
Fibonacci 50% 3.75
Last Price 2.99
Fibonacci 38.2% 2.95
52-Week Low 0.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar